Oculus press releases contain information about products, which may or may not be available in any particular country, and if applicable, may have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws, regulations and medical practices governing the communication of medical or other information about medical products. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product, which is not authorized by the laws and regulations of the country where the reader resides.

Oculus and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.
CONTACT: Media and Investor Contact:         Oculus Innovative Sciences, Inc.         Dan McFadden         Director of Public and Investor Relations         (425) 753-2105

If you liked this article you might like

Skin in the Game: This Dermatology Market Stock Is a Good M&A Bet

Analysts' Actions -- CSX, LinkedIn, Micron and More

Occulus Innovative Sciences (OCLS) Stock Spikes After Receiving New U.S. Patent

Oculus Innovative (OCLS) Is Today's Strong On High Volume Stock

Oculus Innovative Sciences (OCLS) Stock Gains on Earnings Beat